Volume 14, Issue 10 p. 3026-3034
Full Paper

Metal-Ion-Dependent Biological Properties of a Chelator-Derived Somatostatin Analogue for Tumour Targeting

Axel Heppeler Dr.

Axel Heppeler Dr.

Division of Radiological Chemistry, University Hospital of Basel, 4031 Basel, Switzerland, Fax: (+41) 61-265-4699

These two authors contributed equally to the manuscript.

Search for more papers by this author
João P. André Prof.

João P. André Prof.

Centro de Química, Campus de Gualtar, Universidade do Minho, 4710-057 Braga, Portugal

These two authors contributed equally to the manuscript.

Search for more papers by this author
Ingeborg Buschmann Dr.

Ingeborg Buschmann Dr.

Division of Radiological Chemistry, University Hospital of Basel, 4031 Basel, Switzerland, Fax: (+41) 61-265-4699

Search for more papers by this author
Xuejuan Wang Dr.

Xuejuan Wang Dr.

Division of Radiological Chemistry, University Hospital of Basel, 4031 Basel, Switzerland, Fax: (+41) 61-265-4699

Search for more papers by this author
Jean-Claude Reubi Prof.

Jean-Claude Reubi Prof.

Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, Murtenstrasse 31, 3010 Berne, Switzerland

Search for more papers by this author
Michael Hennig Dr.

Michael Hennig Dr.

F. Hoffman-La Roche Ltd, Pharma Research, X-ray Crystallography, CH-4070 Basel, Switzerland

Search for more papers by this author
Thomas A. Kaden Prof.

Thomas A. Kaden Prof.

Institute of Inorganic Chemistry, University of Basel, Spitalstrasse 51, 4056 Basel, Switzerland

Search for more papers by this author
Helmut R. Maecke Prof.

Helmut R. Maecke Prof.

Division of Radiological Chemistry, University Hospital of Basel, 4031 Basel, Switzerland, Fax: (+41) 61-265-4699

Search for more papers by this author
First published: 18 March 2008
Citations: 59

Graphical Abstract

Targeted! Improved pharmacokinetics and tumour targeting of a 1,4,7,10-tetraazacyclododecane-N,N′,N′′,N′′′-tetraacetic acid conjugated somatostatin analogue has been achieved by its coupling to the positron emitter 55Co (57Co; see figure). The structural features of the (radio)metal complex determine its in vivo properties.

Abstract

Somatostatin-based radioligands have been shown to have sensitive imaging properties for neuroendocrine tumours and their metastases. The potential of [55Co(dotatoc)] (dotatoc =4,7,10-tricarboxymethyl-1,4,7,10-tetraazacyclododecane-1-ylacetyl-D-Phe-(Cys-Tyr-D-Trp-Lys-Thr-Cys)-threoninol (disulfide bond)) as a new radiopharmaceutical agent for PET has been evaluated. 57Co was used as a surrogate of the positron emitter 55Co and the pharmacokinetics of [57Co(dotatoc)] were investigated by using two nude mouse models. The somatostatin receptor subtype (sst1–sst5) affinity profile of [natCo(dotatoc)] on membranes transfected with human somatostatin receptor subtypes was assessed by using autoradiographic methods. These studies revealed that [57Co(dotatoc)] is an sst2-specific radiopeptide which presents the highest affinity ever found for the sst2 receptor subtype. The rate of internalisation into the AR4-2J cell line also was the highest found for any somatostatin-based radiopeptide. Biodistribution studies, performed in nude mice bearing an AR4-2J tumour or a transfected HEK-sst2 cell-based tumour, showed high and specific uptake in the tumour and in other sst-receptor-expressing tissues, which reflects the high receptor binding affinity and the high rate of internalisation. The pharmacologic differences between [57Co(dotatoc)] and [67Ga(dotatoc)] are discussed in terms of the structural parameters found for the chelate models [CoII(dota)]2− and [GaIII(dota)] whose X-ray structures have been determined. Both chelates show six-fold coordination in pseudo-octahedral arrangements.